Not yet recruiting NCT07301437
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: liraglutide monotherapy, liraglutide combined with orlistat.
- Who it may be relevant to
- Registry conditions: Overweight and Obese Adults. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Overview
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
Interventions
- Drug liraglutide monotherapy
liraglutide monotherapy - Drug liraglutide combined with orlistat
combination therapy
Primary outcome measures
- weight loss [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
- Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
- No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.
Exclusion criteria
- Allergy to liraglutide, orlistat or excipients
- Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR <30 mL/min
- Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
- Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
- Pregnant or lactating women
- Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07301437 · KY-2025-202